The Global single-use bioreactor market was valued at US$ 3.30 Billion in 2022, and is projected to reach US$ 12.06 Billion by 2030, growing at a CAGR of 17.19% from 2023 to 2030. The global single-use bioreactor market has been proliferating in recent years, driven by a number of factors. These include the increasing demand for biologics, the shift towards more flexible and cost-effective manufacturing processes, and the development of new and innovative technologies.

Browse 215 market data Tables and 96 Figures spread through 312 Pages and in-depth TOC on "Single-use Bioreactors Market Size, Share & Trends Estimation Report By Outlook, By Region, And Segment Forecasts, 2022 - 2030" View detailed Table of Content here-https://www.contrivedatuminsights.com/product-report/single-use-bioreactors-market-248654/

The global single-use bioreactor market has been growing rapidly in recent years, driven by a number of factors. These include the increasing demand for biologics, the shift towards more flexible and cost-effective manufacturing processes, and the development of new and innovative technologies.

Market Dynamics

Developing new and innovative technologies has led to the creation of more advanced single-use bioreactor systems. For example, advances in sensors and automation have improved process control and enabled real-time monitoring of critical process parameters. This has led to improved product quality and higher yields.

The global single-use bioreactor market presents a significant opportunity for growth in the coming years, driven by several factors such as increased demand for biopharmaceuticals, rising adoption of single-use technologies, and increasing focus on reducing manufacturing costs and improving efficiency.

One of the key drivers of the market is the increasing demand for biopharmaceuticals, which are used in the treatment of a wide range of diseases. As biopharmaceuticals are typically more complex and difficult to produce than traditional pharmaceuticals, the use of single-use bioreactors can help to streamline the manufacturing process and reduce costs. Additionally, the growing prevalence of chronic diseases and the aging population is expected to drive demand for biopharmaceuticals, further fueling the growth of the single-use bioreactor market.

Another important factor contributing to the growth of the market is the increasing adoption of single-use technologies by biopharmaceutical manufacturers. Single-use bioreactors offer several advantages over traditional stainless-steel bioreactors, including lower costs, reduced risk of contamination, and greater flexibility in terms of scaling up or down production. These benefits are leading many biopharmaceutical manufacturers to shift towards single-use technologies, further driving the growth of the market.

Single-use bioreactors offer significant cost savings compared to traditional stainless steel bioreactors. They eliminate the need for cleaning and validation between batches, which reduces downtime and enables faster turnaround times. They also require less space and can be easily integrated into existing facilities, providing greater operational flexibility.

Regional Analysis

North America and Europe are currently the largest markets for single-use bioreactors, driven by the presence of a well-established biopharmaceutical industry and a strong regulatory environment. The United States, in particular, is a major market for single-use bioreactors, with many of the leading biopharmaceutical manufacturers based there.

The Asia Pacific region is expected to see the fastest growth in the single-use bioreactor market, driven by the increasing demand for biologics and the growing biopharmaceutical industry in countries such as China, India, and South Korea. These countries are investing heavily in biopharmaceutical manufacturing infrastructure and are expected to become major players in the global biopharmaceutical industry in the coming years.

Competitive Analysis

Thermo Fisher Scientific Inc. and Sartorius AG are currently the leading players in the global single-use bioreactor market, with a strong presence in North America and Europe. They offer a wide range of products and solutions for biopharmaceutical manufacturing, including single-use bioreactors and associated consumables.

Merck KGaA and Danaher Corporation (Pall Corporation) are also major players in the single-use bioreactor market, with a strong focus on innovation and the development of new technologies.

The restraining factors of the global single-use bioreactor market include compatibility issues, regulatory concerns, and lack of standardization. Single-use bioreactors are typically smaller than traditional stainless steel bioreactors, which limits their scalability. While multiple single-use bioreactors can be used in parallel to increase production capacity, this can lead to higher costs and increased complexity. While single-use bioreactors offer cost savings in terms of cleaning and validation, they do require the use of disposable plastic bags, filters, and other consumables. These consumables can be expensive, particularly for large-scale production runs.

In 2018, Merck KGaA formed a strategic partnership with Avacta Group plc to develop a new affinity resin for the purification of biologics. The partnership is expected to combine Merck's expertise in bioprocessing with Avacta's technology for the development of new resins for the purification of biologics.

In 2021, Danaher Corporation announced the acquisition of Aldevron, a leading provider of plasmid DNA, mRNA, and protein production services. The acquisition is expected to strengthen Danaher's position in the biopharmaceutical market and enhance its ability to offer integrated solutions for gene and cell therapy manufacturing.

In 2020, Sartorius AG acquired Biological Industries, a leading provider of cell culture media and sera for the biopharmaceutical industry. The acquisition is expected to enhance Sartorius' product portfolio and expand its presence in the cell culture market.

In 2019, Thermo Fisher Scientific Inc. announced the acquisition of Brammer Bio, a leading provider of viral vector manufacturing services for gene and cell therapy applications. The acquisition is expected to enhance Thermo Fisher's position in the growing gene therapy market.

These strategic developments highlight the importance of partnerships and acquisitions in the single-use bioreactor market, as companies look to expand their product portfolios and offer integrated solutions to customers. As the market continues to grow and evolve, we can expect to see more of these strategic developments in the coming years.

Some of the key players in the global single-use bioreactor market include Thermo Fisher Scientific, Sartorius AG, Merck KGaA, GE Healthcare, Danaher Corporation, Eppendorf AG, and Applikon Biotechnology. These companies are investing in research and development to create more advanced and efficient single-use bioreactor technologies, as well as expanding their manufacturing capacities to meet the growing demand for these products.

Segmentation Analysis of The Global Single-use Bioreactors Market 2016-2030

The report forecasts revenue growth at global, regional, and country matrics and analyzed the latest industry trends in each of the sub-segments ranging from 2016-2030. For this, CDI has segmented the global single-use bioreactors market report based on capacity, vehicle, application, and propulsion type along with regional analysis. 

Product Scope Outlook (Revenue, USD Million, 2018 - 2030)

Single-use bioreactor systems

• Up to 10L
• 11-100L
• 101-500L
• 501-1500L
• Above 1500L

Single-use media bags

• 2D Bags
• 3D Bags
• Others

Single-use Filtration Assemblies

• Other Products

Type Outlook (Revenue, USD Million, 2018 - 2030)

• Stirred-tank SUBs
• Wave-induced SUBs
• Bubble-column SUBs
• Other SUBs

Type of Cell Outlook (Revenue, USD Million, 2018 - 2030)

• Mammalian Cells
• Bacterial Cells
• Yeast Cells
• Other Cells

Molecule Type Outlook (Revenue, USD Million, 2018 - 2030)

• Monoclonal Antibodies
• Vaccines
• Gene Modified Cells
• Stem Cells
• Other Molecules

Application Outlook (Revenue, USD Million, 2018 - 2030)

• Research and Development (R&D) or Process Development
• Bioproduction

End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmaceutical & Biopharmaceutical Companies
• CROs & CMOs
• Academic & Research Institutes

Usage Type Outlook (Revenue, USD Million, 2018 - 2030)

• Lab-scale Production
• Pilot-scale Production
• Large-scale Production

Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• France
• Italy
• Spain
• UK
• Nordic Countries
• Denmark
• Finland
• Iceland
• Sweden
• Norway
• Benelux Union
• Belgium
• The Netherlands
• Luxembourg
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia
• South Korea
• Southeast Asia
• Indonesia
• Thailand
• Malaysia
• Singapore
• Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America